Finally, uncovering novel biomarkers in CRC patients that predict therapeutic response to targeted therapy against IL-25 or IL-33 will be crucial in facilitating their introduction into the clinic for treating CRC in the future. Here, IL33 is linked to colorectal carcinoma.